MarketCap
Facebook
X
TelegramQuarterly report 2025-Q2
added 07-31-2025
Bio-Rad Laboratories Operating Income 2011-2026 | BIO
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income Bio-Rad Laboratories
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 269 M | 338 M | 483 M | 500 M | 421 M | 230 M | -103 M | 119 M | 55.7 M | 167 M | 150 M | 169 M | 264 M | 305 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 500 M | -103 M | 241 M |
Quarterly Operating Income Bio-Rad Laboratories
| 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.1 M | 23.7 M | 64.5 M | 102 M | 44.6 M | 90.9 M | 89.6 M | 61.9 M | - | 94.6 M | 123 M | 146 M | - | 157 M | 125 M | 101 M | - | 110 M | 51.7 M | 74.4 M | - | 57.5 M | 56.4 M | 56.6 M | - | 36.3 M | 43.8 M | 43.6 M | 45.9 M | 38.8 M | -1.7 M | 26.2 M | -28.2 M | 22.7 M | 26.9 M | 20.2 M | - | 32.7 M | 40.2 M | 34.3 M | - | 33.2 M | 45.7 M | 20.5 M | - | 29.1 M | 52.9 M | 35.2 M | - | 65.8 M | 73.3 M | 54.4 M | - | 73.9 M | 68.2 M | 67.1 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 157 M | -28.2 M | 58.9 M |
Operating Income of other stocks in the Medical devices industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Acutus Medical
AFIB
|
-11.7 M | - | -26.83 % | $ 2.62 M |  USA |
 |
LivaNova PLC
LIVN
|
199 M | $ 69.84 | 1.14 % | $ 3.79 B |  Britain |
 |
Allied Healthcare Products
AHPI
|
-1.27 M | - | 3.58 % | $ 2.21 M | USA |
 |
Cognyte Software Ltd.
CGNT
|
-5.13 M | $ 6.61 | 3.44 % | $ 475 M |  Israel |
 |
Apollo Endosurgery
APEN
|
-31.4 M | - | - | $ 475 M | USA |
 |
Alphatec Holdings
ATEC
|
-82.1 M | $ 13.85 | -0.57 % | $ 2.08 B | USA |
 |
Avinger
AVGR
|
-16.6 M | - | -20.74 % | $ 369 K | USA |
 |
AxoGen
AXGN
|
-7.85 M | $ 31.25 | -3.85 % | $ 1.44 B | USA |
 |
Axonics Modulation Technologies
AXNX
|
-64.9 M | - | - | $ 3.31 B | USA |
 |
Aziyo Biologics
AZYO
|
-30.5 M | - | 1.37 % | $ 20.5 M | USA |
 |
Apyx Medical Corporation
APYX
|
-17.3 M | $ 3.46 | -2.26 % | $ 120 M | USA |
 |
Conformis
CFMS
|
-46.3 M | - | - | $ 16.4 M | USA |
 |
BIOLASE
BIOL
|
-17.9 M | - | -13.19 % | $ 166 K | USA |
 |
EDAP TMS S.A.
EDAP
|
-20.5 M | $ 4.63 | 3.58 % | $ 173 M |  France |
 |
Bruker Corporation
BRKR
|
253 M | $ 39.92 | 0.38 % | $ 5.95 K | USA |
 |
BioSig Technologies
BSGM
|
-12.9 M | - | 37.08 % | $ 85.7 M | USA |
 |
Boston Scientific Corporation
BSX
|
3.61 B | $ 74.02 | -1.5 % | $ 110 B | USA |
 |
ClearPoint Neuro
CLPT
|
-19.7 M | $ 15.18 | 4.3 % | $ 410 M | USA |
 |
CONMED Corporation
CNMD
|
103 M | $ 46.01 | -0.07 % | $ 1.43 B | USA |
 |
Cardiovascular Systems
CSII
|
-35.8 M | - | 0.15 % | $ 844 M | USA |
 |
Neovasc
NVCN
|
-31.1 M | - | - | $ 111 M |  Canada |
 |
InMode Ltd.
INMD
|
85.4 M | $ 13.96 | -0.14 % | $ 902 M | Israel |
 |
Cutera
CUTR
|
-156 M | - | -10.19 % | $ 1.99 M | USA |
 |
Delcath Systems
DCTH
|
-12.4 M | $ 10.16 | 2.11 % | $ 290 M | USA |
 |
Dynatronics Corporation
DYNT
|
-2.45 M | - | 14.99 % | $ 929 K | USA |
 |
Eargo
EAR
|
-112 M | - | - | $ 10.2 M | USA |
 |
Electromed
ELMD
|
9.66 M | $ 23.53 | 1.64 % | $ 199 M | USA |
 |
Second Sight Medical Products
EYES
|
-24.7 M | - | -0.97 % | $ 54.4 M | USA |
 |
Establishment Labs Holdings
ESTA
|
-50 M | $ 77.39 | -2.87 % | $ 2.18 B |  Costa-rica |
 |
Nano-X Imaging Ltd.
NNOX
|
-56.7 M | $ 2.46 | 1.23 % | $ 144 M | Israel |
 |
GBS
GBS
|
-10.6 M | - | -0.57 % | $ 7.12 M | USA |
 |
FONAR Corporation
FONR
|
5.31 M | $ 18.54 | -0.16 % | $ 122 M | USA |
 |
Globus Medical
GMED
|
480 M | $ 95.57 | 3.99 % | $ 12.9 B | USA |
 |
Profound Medical Corp.
PROF
|
-30.3 M | $ 7.35 | 2.79 % | $ 180 M | Canada |
 |
Helius Medical Technologies
HSDT
|
-12.4 M | $ 2.18 | 17.84 % | $ 1.33 M | USA |
 |
IRadimed Corporation
IRMD
|
22 M | $ 100.38 | 1.3 % | $ 1.27 B | USA |
 |
Invacare Corporation
IVC
|
-80.5 M | - | - | $ 24.7 M | USA |
 |
Integra LifeSciences Holdings Corporation
IART
|
28.4 M | $ 11.54 | 0.09 % | $ 889 M | USA |
 |
Inogen
INGN
|
-42.5 M | $ 6.07 | 3.94 % | $ 144 M | USA |